Toxicity profile of thal-dex regime in patients with multiple myeloma


  • Dawnji S. R. Department of Pharmacology, Government Medical College, Trivandrum, Kerala, India
  • Reeja R. Department of Pharmacology, Government Medical College, Kollam, Kerala, India
  • Rakesh Praveen Raj M. R. Department of General Surgery, Azeezia Medical College, Kollam, Kerala, India



Dexamethasone, Multiple myeloma, Thal-Dex toxicity, Thalidomide


Background: To study the spectrum, incidence and severity of toxicity among Multiple Myeloma patients receiving Thal-Dex in South Indian population.

Methods: Between November 2005 and November 2005, 25 adult patients with previously- untreated Multiple Myeloma were assigned to receive Thal-Dex at Regional Cancer Centre, Trivandrum. During chemotherapy, patients were followed-up to detect the development of any toxicity symptoms. The toxicities recorded, were graded according to the criteria of the World Health Organization toxicity-guidelines.

Results: In the 25 patients who received Thal-Dex, peripheral neuropathy, infection and constipation were significantly seen, while gastrointestinal toxicities were seen to a lesser extent, and haematological toxicities were low.

Conclusions: The Thal-Dex regimen was tolerated well by majority of the patients and showed favourable toxicity profile, reiterating its acceptability as a front line antimyeloma regimen


Robert A. Vesico, James R Bernson. Myeloma, Macroglobulinemia and amyloidosis- Cancer treatment-Haskell 5th edition. 1999:1503-1539.

Gareth Morgan and Peter Selby-Myeloma-Oxford Textbook of Oncology, 2nd edition; 15-12:2419-55.

Vincent T, Divetta, Samuel Hellman, Steva A. Rosenberg. Antiangiogenesis agents: Cancer Principles and Practice of Oncology. 6th edition; 63:2765-70.

Singhal S, Metha J, Desikan R. Antitumor activity of Thalidomide in refractory Multiple Myeloma. NEJM. 1999;341:1565-71.

Attal M, Harousseau JL, Stoppa AM. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in Multiple Myeloma. NEJM. 1996;336:91-7.

Bardos A, Barlogie B, Siegel E. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600-7.

Hussien MA, Wood L, Hsi E. Phase II trial of pegylated liposomal doxorubicin, Vincristine, and reduced-dose Dexamethasone combination therapy in newly diagnosed myeloma patients. Cancer. 2002;95:2160-8.

Richardson P, Anderson. Thalidomide K. Dexamethasone: A new standard of care for initial therapy in multiple myeloma. J Clin Oncol. 2006;132:155-67.

Rajkumar SV, Blood E, Vesole D. Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:31-6.

Weber D, Rankin K, Ga M. Thalidomide alone or with Dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-9.

Cavo M, Zamagni E, Tosi P. Superiority of Thalidomide and Dexamethasone over VAD as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005:106:35-39.

Dimopoulos MA, Eleutherkis V. Adverse effects of thalidomide administration in patients neoplastic diseases. Am J Med. 2004;117:508-15.

Badrose AZ, Siegal E, Bodenner D. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med. 2002;112:412-3.

Rajkumar. Blood AHS; Annual meeting. Abstract-2004;104:205.




How to Cite

R., D. S., R., R., & M. R., R. P. R. (2017). Toxicity profile of thal-dex regime in patients with multiple myeloma. International Journal of Basic & Clinical Pharmacology, 6(5), 1073–1077.



Original Research Articles